We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04672395
Recruitment Status : Active, not recruiting
First Posted : December 17, 2020
Last Update Posted : August 29, 2022
Sponsor:
Collaborators:
Coalition for Epidemic Preparedness Innovations
International Vaccine Institute
Information provided by (Responsible Party):
Clover Biopharmaceuticals AUS Pty Ltd

Brief Summary:
The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 12 Years and Older.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccine Biological: Placebo; 0.9% saline Biological: SCB-2019 vaccine Biological: SCB-2019 vaccine for Placebo Phase 2 Phase 3

Detailed Description:

This study will assess the efficacy against COVID-19, immunogenicity, reactogenicity, and safety of CpG 1018/Alum-adjuvated SCB-2019 vaccine. The COVID-19 pandemic has resulted in high morbidity and mortality, caused major disruption to healthcare systems, and has had significant socioeconomic impacts. Currently, only limited treatment options are available against COVID-19 and accelerated vaccine development is urgently needed. Several COVID-19 vaccines were recently authorized in some countries, but the global supply is insufficient for pandemic control. Additional safe and effective vaccines for COVID-19 prevention would have significant public health impact.

Placebo recipients will be offered two doses of SCB-2019 vaccine at defined points as part of the study.

Adults participants who received SCB-2019 vaccine, will be given a third dose of the SCB-2019 vaccine at least 4 months after the second dose to assess the safety and efficacy of a booster (third) dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31454 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Each subject will receive 2 doses of their assigned treatment on Days 1 and 22. Booster dose will be given at least 4 months after the second dose (Day 1A for booster dose). The treatment will be administered IM in the deltoid region of the upper non-dominant arm
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
Actual Study Start Date : March 24, 2021
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
CpG 1018/Alum-adjuvanted SCB-2019 vaccine
Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccine
Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22

Placebo Comparator: Group 2
Placebo Comparator: 0.9% Saline
Biological: Placebo; 0.9% saline
Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22

Experimental: Booster dose of SCB-2019
Adult SCB-2019 recipients will receive 1 dose of SCB-2019 at least 4 months after the second dose
Biological: SCB-2019 vaccine
Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant

Placebo Comparator: Vaccination of placebo recipients with SCB-2019
Placebo participants will be offered two doses of SCB-2019 vaccine
Biological: SCB-2019 vaccine for Placebo
Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart




Primary Outcome Measures :
  1. Number of Participants with a First Occurrence of COVID-19 of Any Severity Starting 14 Days after Second Dose of SCB-2019 [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  2. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [ Time Frame: Up to Day 8 (7 days after first dose) and up to Day 29 (7 days after second dose) ]
  3. Number of Participants with Unsolicited AEs [ Time Frame: Up to Day 43 (21 days after each dose) ]
  4. Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs) [ Time Frame: Up to Day 389 (1 year after second dose) ]
  5. Non-inferiority of the neutralizing titers after third dose compared to the neutralizing titers after second dose [ Time Frame: 14 days after third dose ]
  6. Non-inferiority of the neutralising titers in adolescents versus young adults. [ Time Frame: 14 days after second dose ]

Secondary Outcome Measures :
  1. Number of Participants with a First Occurrence of Moderate-to-Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019 [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  2. Number of Participants with First Occurrence of Any Laboratory-Confirmed SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  3. Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of SCB-2019 or Placebo [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  4. Number of Participants with First Occurrence of Any Laboratory-Confirmed Asymptomatic SARS-CoV-2 infection Starting 14 Days after Second Dose of SCB-2019 or Placebo [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  5. Burden of Disease Score of COVID-19 or SARS-CoV-2 Infection Cases Starting 14 Days after Second Dose of SCB-2019 or Placebo [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  6. Number of Participants with a First Occurrence of COVID-19 of Any Severity, Associated with Hospitalization, Starting 14 Days after Second Dose of SCB-2019 or Placebo [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  7. Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of evidence of prior SARS-CoV-2 Infection [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  8. Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of SCB-2019 or Placebo, regardless of risk of severe COVID-19 [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  9. Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of SCB-2019 or Placebo [ Time Frame: Day 15 up to Day 22 ]
  10. Number of Participants with a First Occurrence of COVID-19 of Any Severity caused by SARS-CoV-2 variants of concern starting 14 days after Second Dose [ Time Frame: Day 36 up to Day 389 (1 year after second dose) ]
  11. Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  12. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  13. Number of Participants with Seroconversion for SARS-CoV-2 Specific nAb [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  14. Geometric Mean Titer (GMT) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  15. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  16. Number of Participants with Seroconversion for of SARS-CoV-2 antibodies competing for binding of S protein to the human ACE2 receptor [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  17. Geometric Mean Titer (GMT) of SCB-2019 binding antibody [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  18. Geometric Mean Fold Rise (GMFR) of SCB-2019 binding antibody [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  19. Number of Participants with Seroconversion for SCB-2019 binding antibody [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  20. Geometric Mean Titer (GMT) of Trimer-Tag binding antibody [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  21. Geometric Mean Fold Rise (GMFR) of Trimer-Tag binding antibody [ Time Frame: Day 1, Day 22, Day 35, Day 205, and Day 389 ]
  22. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [ Time Frame: Up to 7 days after booster dose ]
  23. Number of Participants with Unsolicited AEs [ Time Frame: Up to 21 days after booster dose ]
  24. Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs) [ Time Frame: Up to 6 months after booster dose ]
  25. Geometric Mean Titer (GMT) of SARS-CoV-2 Specific nAb [ Time Frame: Day 1A, Day 15A (15 days after booster), and Day 389A (6 months after booster) ]
  26. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb [ Time Frame: Day 1A, Day 15A (15 days after booster), and Day 389A (6 months after booster) ]
  27. Number of Participants with Seroconversion for SARS-CoV-2 Specific nAb [ Time Frame: Day 1A, Day 15A (15 days after booster), and Day 389A (6 months after booster) ]
  28. Geometric Mean Titer (GMT) of SCB-2019 binding antibody [ Time Frame: Day 1A, Day 15A (15 days after booster), and Day 389A (6 months after booster) ]
  29. Geometric Mean Fold Rise (GMFR) of SCB-2019 binding antibody [ Time Frame: Day 1A, Day 15A (15 days after booster), and Day 389A (6 months after booster) ]
  30. Number of Participants with Seroconversion for SCB-2019 binding antibody [ Time Frame: Day 1A, Day 15A (15 days after booster), and Day 389A (6 months after booster) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or females ≥12 years of age, inclusive*.
  2. Participants who are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, the electronic completion of the COVID-19 ePRO and other study procedures.
  3. Healthy adult or adolescent subjects or adult or adolescent subjects with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.

    *Note: The first 200 individuals enrolled in the Phase 2 part of the study should be healthy subjects 18 to 64 years or age without comorbidities associated with a high risk of severe COVID-19

  4. Female subjects who are WOCBP are eligible to participate in the study if not pregnant, not breastfeeding, and at least 1 of the following criteria apply:

    • WOCBP must have a negative urine pregnancy test prior to each vaccination. A confirmatory serum pregnancy test may be conducted at the investigator's discretion.
    • They must be using a highly effective licensed method of birth control for 30 days prior to the first vaccination and must agree to continue such precautions during the study until 90 days after the second vaccination.
  5. Male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 6 months after the last dose of the study vaccine/placebo and also refrain from donating sperm during this period.
  6. Individuals (or their legally acceptable representative based on local regulations) willing and able to give an informed consent, prior to screening. For adolescent subjects: informed assent signed by adolescents and informed consent signed by the parent(s) or legally acceptable representative(s) as per local requirements.
  7. Applicable for HIV-positive individuals only if:

They are medically stable at screening, as determined by the investigator, and free of opportunistic infections in the 1 year prior to first study vaccination, and They have an HIV-1 viral load <1000 copies/mL within 45 days of randomization in the study, and They are receiving highly active antiretroviral therapy (HAART) for at least 3 months before screening. Changes in antiretroviral dosage within 3 months of entering the study are allowed, as are exchanges in pharmacological formulations.

Exclusion Criteria:

  1. Individuals with laboratory-confirmed SARS-CoV-2 infection (e.g., a positive RT-PCR* or Rapid COVID-19 Antigen test) at screening or within 14 days prior to enrollment.
  2. Individuals with behavioral or cognitive impairment (including drug and alcohol abuse) in the opinion of the investigator.
  3. Individuals with any progressive or severe neurologic disorder, seizure disorder, or history of Guillian-Barré syndrome.
  4. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, e.g., for cancer or an autoimmune disease, or planned receipt during the study period.
  5. Individuals who are pregnant, or breastfeeding, or planning to become pregnant during the study period.
  6. Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccine (SCB-2019, CpG1018 Adjuvant and Aluminum hydroxide components).
  7. Individuals who have a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix which have been cured, or other malignancies with minimal risk of recurrence).
  8. Individuals who have received any other investigational product within 30 days prior to Day 1 or intent to participate in another clinical study at any time during the conduct of this study.
  9. Individuals who have received previous vaccination with any coronavirus vaccine.
  10. Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 14 days after the second vaccination.
  11. Individuals with known bleeding disorder that would, in the opinion of the investigator, contraindicate intramuscular injection.
  12. Individuals who received any blood/plasma products or immunoglobulins within 60 days prior to Day 1 or plan to receive it during the study period.
  13. Individuals with any condition that, in the opinion of the investigator, may increase the risk of study participation or interfere with the assessment of the primary study objectives.
  14. Individuals with fever >37.8°C (irrespective of method), or any acute illness at baseline (Day 1) or within 3 days of randomization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04672395


Locations
Show Show 31 study locations
Sponsors and Collaborators
Clover Biopharmaceuticals AUS Pty Ltd
Coalition for Epidemic Preparedness Innovations
International Vaccine Institute
Investigators
Layout table for investigator information
Study Chair: Igor Smolenov, MD, PhD Clover Biopharmaceuticals AUS Pty Ltd
Publications:
Food and Drug Administration letter. Device: BinaxNOW COVID-19 Ag Card. 26 August 2020. https://www.fda.gov/media/141567/download. Accessed on 15 September 2020.
Food and Drug Administration Guidance Document: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at https://www.fda.gov/media/73679/download. Accessed on 15 September 2020.
Safety Platform for Emergency vACcines (SPEAC). D2.3 Priority List of Adverse Events of Special Interest: COVID-19. V1.1 Date 05 March 2020. https://media.tghn.org/articles/COVID-19_AESIs_SPEAC_V1.1_5Mar2020.pdf. Accessed on 15 September 2020.
Chan ISF, Bohidar NR (1998) Exact power and sample size for vaccine efficacy studies, Communications in Statistics - Theory and Methods 1998;27(6):1305-22.
Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. Stat Biopharm Res 2013;5(4):311-20.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Clover Biopharmaceuticals AUS Pty Ltd
ClinicalTrials.gov Identifier: NCT04672395    
Other Study ID Numbers: CLO-SCB-2019-003
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: August 29, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Vaccines
1018 oligonucleotide
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic